


## PHARMACEUTICAL 2023



## Karuna Therapeutics Inc. Rank 23 of 446





## PHARMACEUTICAL 2023



## Karuna Therapeutics Inc. Rank 23 of 446



The relative strengths and weaknesses of Karuna Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karuna Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Karuna Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 276%, being 233% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,154,769
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	33,946
Liabilities, Non-Current	3,150
Other Assets	5,364
Other Compr. Net Income	-2,793
Other Expenses	1,418
Other Liabilities	0
Other Net Income	14,758
Other Revenues	10,637
Property and Equipment	3,201
Research and Development	224,247
Selling, General and Administrative Expense	76,066

Output Variable	Value in 1000 USD
Assets	1,163,334
Liabilities	37,096
Expenses	301,731
Revenues	10,637
Stockholders Equity	1,126,238
Net Income	-276,336
Comprehensive Net Income	-277,732
Economic Capital Ratio	276%

